These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 28523353)

  • 1. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
    Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Zhu H; Zhao S; Zuo C; Ren F
    AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.
    Noda Y; Kanematsu M; Goshima S; Suzui N; Hirose Y; Matsunaga K; Nishibori H; Kondo H; Watanabe H; Kawada H; Kawai N; Tanahashi Y; Bae KT
    Eur Radiol; 2015 Oct; 25(10):3009-16. PubMed ID: 25854217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Zhang L; Zhao H; Jiang H; Zhao H; Han W; Wang M; Fu P
    Abdom Radiol (NY); 2021 Dec; 46(12):5618-5628. PubMed ID: 34455450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
    Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT-correlation with microvascular density.
    Marcon J; Graser A; Horst D; Casuscelli J; Spek A; Stief CG; Reiser MF; Rübenthaler J; Buchner A; Staehler M
    Eur Radiol; 2020 Jan; 30(1):1-10. PubMed ID: 31278580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of
    Betsunoh H; Sakamoto S; Kaji Y; Nukui A; Kobayashi M; Yashi M; Hayashi K; Anzai N; Kamai T
    Anticancer Res; 2021 Oct; 41(10):5179-5188. PubMed ID: 34593470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
    Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
    Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance and prognostic value of preoperative
    Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
    Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of early dynamic and delayed post-diuretic
    Sharma A; Mete UK; Sood A; Kakkar N; Gorla AK; Mittal BR
    Br J Radiol; 2017 Apr; 90(1072):20160787. PubMed ID: 28256904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-[
    Zhao Y; Wu C; Li W; Chen X; Li Z; Liao X; Cui Y; Zhao G; Liu M; Fu Z
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):570-579. PubMed ID: 32814979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-stage clear cell tubulopapillary renal cell carcinoma: imaging features and distinction from clear cell and papillary subtypes.
    Mnatzakanian GN; Shinagare AB; Sahni VA; Hirsch MS; Silverman SG
    Abdom Radiol (NY); 2016 Nov; 41(11):2187-2195. PubMed ID: 27383741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.